303. AAV Capsid Evolution for Enhanced Antibody Delivery to Human Muscle for Use in Next-Generation HIV Vaccines

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33912-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prospects of Next-Generation Vaccines for Bluetongue

Frontiers in Veterinary Science
Veterinary
2019English

Capsid-Expressing DNA in AAV Vectors and Its Elimination by Use of an Oversize Capsid Gene for Vector Production

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2010English

304. Deriving Useful Data From Next-Gen Sequencing of AAV Capsid Libraries

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Aluminum Oxide Nanowires as Safe and Effective Adjuvants for Next-Generation Vaccines

Materials Today
Mechanics of MaterialsMaterials ScienceCondensed Matter PhysicsMechanical Engineering
2019English

Advances in Antibody-Based HIV-1 Vaccines Development

Vaccines
Drug DiscoveryInfectious DiseasesImmunologyPharmacology
2020English

Striking a Balance in an Antibody Network: A Roadmap for HIV-1 Vaccines

Journal of Clinical Investigation
Medicine
2019English

Development of Next Generation Antibody-Based Immunotherapy for Childhood Cancer Neuroblastoma

The Lancet
Medicine
2016English

Md3 - From Drug-Delivery Device to Disease Management Tool: A Study of Patient Preferences for Enhanced Features in Next Generation Self-Injection Devices

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

310. Development of Generation X Recombinant AAV Vectors for Human Gene Therapy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy